Aclaris to Release Phase 1a SAD/MAD ATI-052 Results and ATI-2138 Indication Choice
Aclaris Therapeutics will release full results from its Phase 1a SAD/MAD trial of anti-TSLP/IL-4R bispecific ATI-052 and disclose the chosen indication for ITK/JAK3 inhibitor ATI-2138 before U.S. markets open on April 28, 2026. A webcast and conference call at 8:30 AM EST will present detailed data and next steps.
1. Clinical Update Timing
Aclaris will provide complete results from its Phase 1a single and multiple ascending dose (SAD/MAD) study of ATI-052 and announce the lead indication for its ITK/JAK3 inhibitor ATI-2138 before U.S. markets open on April 28, 2026.
2. ATI-052 Phase 1a Trial
The Phase 1a trial evaluated safety, tolerability and pharmacokinetics of ATI-052, an anti-TSLP/IL-4R bispecific antibody, across single and multiple ascending dose cohorts to inform dose selection for future studies.
3. ATI-2138 Indication Selection
Aclaris completed its lead indication selection process for ATI-2138, an oral ITK/JAK3 inhibitor, choosing the most promising immuno-inflammatory disease target based on preclinical and early clinical criteria.
4. Webcast and Call Logistics
A webcast and conference call will begin at 8:30 AM EST on April 28, 2026, featuring slide presentations; live access and a 30-day archive will be available via the Events page on Aclaris’ investor website.